Abstract

The aim of the work is an attempt to design, development and evaluation of fast dissolving tablets of Levosalbutamol sulphate by direct compression method with the aid of superdisintegrant addition. Levosalbutamol (LS) is the R – enantiomer of short acting beta2 adrenergic receptor agonist of salbutamol used to treat asthma and Chronic obstructive pulmonary disease. Nine formulations were prepared by using three different superdisintegrants in varying concentration in such way that total weight of the tablet remains same. The drug-polymer incompatibility was analysed by FTIR studies. All the formulated tablets were subjected for pre and post-compression evaluation parameters. From the FTIR studies the drug-polymer compatibility were confirmed. The pre-compression parameters like bulk density, tapped density, Carr’s index and angle of repose was determined. The optimized formulation showed acceptable flow properties. The post-compression parameters like the thickness, hardness, friability and in vitro dispersion time, wetting time, water absorption ratio and in- vitro drug release were carried out and the values were found to be within IP limits. Among the nine formulations, the formulation containing Kyron T 314 (F9) showed highest drug release of 97.71 % than other formulations.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.